MLAB vs STE
MLAB: Mesa Laboratories provides essential quality control and life sciences tools designed to protect patient safety and ensure regulatory compliance in highly regulated healthcare and pharmaceutical markets. STE: A premier provider of essential infection prevention, sterilization, and procedural care solutions for healthcare and life sciences organizations worldwide.
Side-by-side fundamentals
| Metric | MLAB | STE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $126.06 | $210.76 | |
| Market cap | $705M | $20.5B | |
| P/E as of 2026-10-08 | 104.39 | 26.55 | STE lower |
| Net margin FY2026, SEC XBRL | +2.7% | +13.2% | STE higher |
| Gross margin FY2026, SEC XBRL | +63.5% | +44.2% | MLAB higher |
| Operating margin FY2026, SEC XBRL | +7.4% | +18.6% | STE higher |
| ROE FY2026, SEC XBRL | +3.6% | +10.9% | STE higher |
| ROA FY2026, SEC XBRL | +1.6% | +7.3% | STE higher |
| Debt / equity as of 2026-09-03 | 0.81 | 0.27 | STE lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.4% | +8.7% | STE higher |
| Revenue CAGR (3y) SEC XBRL | +4.4% | +9.4% | STE higher |
| Dividend yield as of 2026-09-03 | +0.5% | +1.3% | STE higher |
| Dividend streak (yrs) SEC XBRL | 8 | 10 | STE higher |
| Beta as of 2026-09-03 | 1.43 | 0.50 | |
| 1-year return as of 2026-10-08 close | +78.2% | -13.0% | MLAB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.